Malignant Lymphoma in the Parasellar Region

Table 2

Clinical summary of 17 patients with SPL.

Age, sex	Clinical presentation	Endocrine abnormality	Pathology	Therapy	OS (month)
47, M [21]	HA, CN VI	Hypo,	HL	Chemo + Ste + Rd	4.5, alive
19, M [25]	HA, F, S&WL, dyspnea, seizure	Hypo, DI	C	Chemo + Ste	18, dead
56, M [24]	CN III	Hypo,	NHL	Chemo + MTx + Rd	25, alive
56, F [28]	F, S&WL, anorexia	DI, PRL	T-cell	Chemo + Ste	4.5, dead
50, M [22]	F, S&WL	—	T-cell	Chemo	72, alive
33, M [18]	F, S&WL, CN III/IV/VI	—	HL	Chemo	62, alive
70, F [29]	F, S&WL	Hypo,	—	—	1.75, dead
77, M [26]	Weakness	Hypo,	NHL	Ste	2.25, dead
64, M [27]	Abdominal pain	DI	B-cell	Chemo + MTx	36, alive
37, M [19]	HA	DI	B-cell	Chemo + i.t. MTx	10, alive
72, F [10]	F, S&WL, weakness	Hypo,	B-cell	Chemo	12, alive
70, M [30]	F, S&WL	SIADH	B-cell	Chemo + Ste	n.d., dead
59, M [32]	HA, CN III	—	B-cell	Chemo + i.t. MTx	18, alive
53, M [32]	HA, F, S&WL	DI	B-cell	Chemo + i.t. MTx + Rd	5, alive
41, M [23]	HA, F, S&WL, CN II	DI	T-cell	Chemo + Rd	18, dead
70, F [33]	HA, CN III	Hypo, DI	B-cell	—	n.d.
78, F (Our case)	F, S&WL	DI	B-cell	Chemo + Rd	48, alive

B-cell: B-cell lymphoma; Chemo: chemotherapy; CN: cranial nerve palsy; DI: diabetes insipidus; F, S&WL: fever, night sweat, and weight loss; HA: headache; HL: Hodgkin lymphoma; i.t.: intrathecal; n.d.: not described; NHL: non-Hodgkin lymphoma; OS: overall survival; Rd: radiotherapy; SIADH: syndrome of inappropriate secretion of ADH; Ste: steroid; T-cell: T-cell lymphoma; —: none.